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Cancer represents one of the major health burdens and a leading cause of mortality 
worldwide, responsible for millions of deaths annually. The latest survey of the Global Cancer 
Observatory (GLOBOCAN) series – published by International Agency for Research on Cancer 
(IARC) – estimated 19.3 million new cancer cases and 9.6 million cancer-related deaths in 
2020. Among females, breast cancer is the most frequently diagnosed type and the principal 
cause of cancer-related deaths, responsible for 2.26 million new cases and 685,000 deaths, 
while cervical neoplasms are the fourth most common, both in incidence and mortality, with 
approximately 604,000 new cases and 342,000 deaths. Although a very high proportion of 
cancer cases may be treated successfully with improved survival outcome by early diagnosis 
(owning to milder symptoms or asymptomatic characteristic of the early stages), due to the lack 
of resources and protocols in many countries, neoplasms are often identified only in their 
advanced stages. Moreover, success of the therapy is limited by de novo or acquired resistance 
against anticancer drugs. Besides rapid advancement in preventive, diagnostic and therapeutic 
strategies, in the light of previously described facts, novel treatment options of breast and 
cervical tumors are eagerly awaited. 
Biologically active molecules with a steroidal framework constitute a diverse and 
extensive group of organic compounds. Hundreds of natural derivatives are found in plants, 
fungi and animals, while preparation of semisynthetic or synthetic analogues is one of the 
prominent fields of pharmaceutical research. Sexual steroids (estrogens, progestogens and 
androgens) are essential parts of human hormonal system. Plenty of these compounds, as well 
as their semi-synthetic and synthetic derivatives, are used for therapeutic purposes, including 
anabolics, hormonal contraceptives or as part of hormone replacement therapy. Besides their 
physiological impacts, sexual steroids are also involved in the development of numerous 
hormone-dependent malignancies, such as prostate, breast, endometrial cancer or hormone-
independent types, e.g., bladder, lung, colorectal and brain tumors as well. Recent studies 
suggest that some natural androstanes, as well as their A- or D-ring modified derivatives are 
able to inhibit proliferation of breast or gynaecological cancer cells, induce cell cycle 
disruptions and have proapoptotic, antimigratory and antimetastatic properties, without 
hormonal or antihormonal characteristic. Comprehensive analysis of structure-activity 
relationships proved that the incorporation of bulky heterocyclic moiety on the D-ring may 





During our experiments, four novel, heterocyclic, D-ring modified androstane 
derivatives were examined. 3β-Hydroxy-17-[1’-(4’’-cyanophenyl)-4’-hydroxymethyl-1’H-
pyrazol-3’-yl]androsta-5,16-diene exerted pronounced antiproliferative properties on breast 
cancer cell lines as reported previously.55 The aim of the present study was to examine the 
antiproliferative and antimetastatic characteristics and the underlying mechanism of action of 
these promising compounds with in vitro and in vivo experiments on breast and gynaecological 
tumor cell lines. 
The purposes of the performed experiments were as follows: 
 Caracterization of antiproliferative properties of the tested compounds on breast and 
gynaecological cancer cell lines, and the determination of their IC50 values by 
standard MTT assay. 
 Estimation of tumor selectivity indices on all of the investigated cell lines compared 
to a non-cancerous cell line (NIH/3T3). 
 Detection of apoptosis-inducing effects of the tested compounds, and their pathway 
using Hoechst/propidium iodide and Annexin V/propidium iodide fluorescent 
double staining methods, cell cycle analysis, colorimetric determination of caspase-
3 activity and mitochondrial membrane potential assay (JC-1 assay). 
 Demonstrating the possible androgenic/antiandrogenic activity of the tested 
compounds, owing to the androstane skeleton by yeast androgen screening assay 
(YAS). 
 Examination of the inhibitory effects of the tested compounds to the early steps of 
metastasis formation such as migration, invasion and intravasation, carrying out 
wound-healing, Boyden chamber and circular chemorepellent-induced defects 
(CCIDs) assays. 
 Analysis of expression level of tumor markers upon treatment with the tested 
compounds. 
 Investigation of in vivo administration of the tested compounds on the 4T1 
ortothopic mouse breast cancer model.  
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3. Materials and methods 
3.1 Chemicals 
Synthesis and chemical characterization of the test compounds were carried out by Éva 
Frank et al. as reported previously or by the colleagues of the Department of Chemistry, 
Biochemistry and Environmental Protection, University of Novi Sad, Serbia. 
 
Figure 1. Chemical structures of the tested compounds (1-4). 
3.2 Cell lines 
HeLa, SiHa, C33A, A2780, MCF-7, T-47D, MDA-MB-231 and NIH/3T3 cells were 
maintained in Eagle’s Minimal Essential Medium (EMEM), supplemented with 10% fetal 
bovine serum (FBS), 1% non-essential amino acid (NEAA) mixture and 1% penicillin, 
streptomycin and amphotericin B mixture at 37°C in a humidified carbon dioxide (CO2) 
atmosphere. iLEC cells were grown in EGM-2MV medium under the same conditions. MDA-
MB-361 cells were cultivated in L-15 medium, complemented with 20% FBS, 1% NEAA 
mixture and 1% antibiotic/antimicotic mixture at 37 °C, under humidified carbon dioxide-free 
circumstances. 4T1 mouse breast cancer cells were cultured in RPMI medium containing 10% 
FBS, 1% NEAA mixture and 1% antibiotic solution in CO2 incubator at 37°C. 
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3.3 MTT-assay (antiproliferative assay) 
Proliferation and viability of cells upon treatment with the test compounds were 
investigated by the standard MTT assay. All cell types were maintained under the cell culturing 
circumstances described previously, and were seeded into 96-well plates and were treated with 
increasing concentrations of the test substances (0.1-30 µM). After 72 h of incubation, MTT 
solution was added to the wells for 4 h and the precipitated, blue formazan crystals were 
dissolved in DMSO. Finally, absorbance values were recorded by a microplate reader at 545 
nm and normalized six-point dose-response curves were evaluated by GraphPad Prism 5.01 
software. 
3.4 Hoechst/Propidium iodide fluorescent double staining 
Apoptosis or necrosis-related changes in cell morphology and membrane integrity were 
investigated by Hoechst 33258 and propidium iodide (PI) fluorescent staining. Suspension of 
MCF-7 and SiHa cells were seeded into 96-well plates and were treated with increasing 
concentrations of compound 1 for 24 h. After treatment period, cells were stained in the dark, 
under cell culturing conditions described above for 1 hour and images were taken by the 
QCapture Pro software and a Nikon Eclipse TS100 fluorescence microscope. Nuclei emitting 
fluorescence were counted and the proportion of intact, apoptotic and necrotic cell populations 
were expressed as percentages. 
3.5 Apoptosis Assay 
MCF-7, MDA-MB-231, SiHa and C33A cells were seeded into 24 well cell culture 
plates and were treated with different concentrations of the test compound (1) for 24 h. Next, 
cells were washed with phosphate-buffered saline (PBS), harvested with trypsin and pooled 
with the collected supernatants. Samples were centrifuged and pellets were resuspended in 
Annexin V binding buffer accompanied by staining procedure with Annexin V-Alexa488 and 
PI solution in the dark at room temperature for 15 minutes. For each sample, 10 000 events 





3.6 Cell cycle analysis 
Briefly, MCF-7, MDA-MB-231, SiHa and C33A cells were seeded onto 24-well plates 
and were exposed to our drug candidate (1) for 48 h or 72 h. The samples were washed with 
PBS, collected, pooled with the corresponding supernatants and centrifuged. The DNA content 
of resuspended cells were labelled with PI in DNA staining solution in the dark, at room 
temperature for 30 min. Analysis of at least 20,000 events/sample were carried out by the 
FACSCalibur flow cytometer and the Kaluza Analysis software. 
3.7 Determination of caspase-3 activity  
SiHa cells were grown in cell culture flasks under standard cell culturing conditions and 
treated for 24, 48 and 72 h. Thereafter, cells were collected with a special cell scraper tool and 
counted. Samples were centrifuged, supernatants were gently removed and cells were lysated 
by required amount of lysis buffer of the kit on ice for 20 min. Next, lysates were centrifuged 
and 5 µL portions of the supernatants were incubated overnight with 10 µL substrate (acetyl-
Asp-Glu-Val-Asp-p-nitroanilide) and assay buffer in 96-well plate at 37°C according to the 
manufacturer's protocol. Finally, absorbance values of the colorful substrate cleaved by 
caspase-3 in samples were detected at 405 nm with a microplate reader. 
3.8 Mitochondrial membrane potential assay (JC-1 staining) 
MCF-7, MDA-MB-231, SiHa and C33A cells were grown and harvested under standard 
cell culturing conditions, and were seeded onto 24-well plates. After 12 h (MCF-7, MDA-MB-
231) or 24 h (SiHa, C33A) treatment of compound 1, samples were washed, collected and 
centrifuged. After that, pellets were resuspended and stained with JC-1 solution (5 μg/ml) at 
37°C for 5 minutes. Finally, red and green fluorescence of the cells were investigated on FL2 
(585/42 nm) - FL1 (530/30 nm) channels by the FACSCalibur flow cytometer.  
3.9 Yeast Androgen Screen assay (YAS) 
The yeast cells were grown in humidified air at 31°C on an orbital shaker. Next, they 
were plated onto assay plates and were incubated in the presence of the CPRG substrate and 
the test substance and/or 5α-dihydrotestosterone (DHT) used as reference agent, for 2 days. 
Androgenic activity triggers the expression of β-galactosidase from the reporter gene and this 
enzyme can convert the yellow CPRG substrate into a red product. Absorbance of samples were 
detected at 570 nm and 690 nm.  
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3.10 Wound-healing assay 
In our experiments, MCF-7 and SiHa cells were implanted in special silicon inserts, 
which were placed onto 24-well plates, in standard EMEM medium, containing 10% FBS. After 
overnight incubation, inserts were removed cautiously and the confluent monolayers with 
certain cell-free areas were washed with PBS. Cells were treated with sub-antiproliferative 
concentrations of compound 1 in EMEM medium containing 2% FBS, and images were taken 
by a Nikon Eclipse TS100 microscope 0, 24 and 48 h post-treatment. 
3.11 Boyden chamber assay 
After prehydration of a polyethylene terephthalate (PET) membrane in special Boyden 
chamber inserts placed onto a 24-well plate, cell suspension prepared in serum-free EMEM 
with sub-antiproliferative concentrations of the test substance (1) was nested in the upper 
compartments and EMEM medium supplemented with 10% FBS was applied as a 
chemoattractant in the lower chambers. After 24 h incubation, invading cells were fixed in ice 
cold 96% ethanol and were stained by 1% crystal violet dye. Images were taken by the Nikon 
Eclipse TS100 microscope and the number of invading cells was counted. 
3.12 Circular chemorepellent-induced defects assay (CCIDs) 
Initially, MCF-7 cells suspended in EMEM medium, complemented with a 
methylcellulose solution were plated onto U-bottom 96-well plates, centrifuged and incubated 
for 3 days to form spheroids. Non-cancerous human lymphatic endothelial cells (iLEC) were 
seeded onto 24-well plates and grown to approximately 100% of confluency. Before 
measurement, iLEC monolayers were stained with CellTracker Green dye. The endothelial 
barriers and selected tumor spheroids were pre-incubated with compound 1 or defactinib or 
epiandrosterone for 20 minutes, separately. After pretreatment, the spheroids were placed upon 
the iLEC cell monolayer and incubated in the presence of the test compounds for 4 hours. 
Finally, images of at least 12 spheroids per condition were taken by fluorescent Axiovert 
microscope. 
3.13 Single cell mass cytometry 
Briefly, MDA-MB-231 cells were seeded and were incubated with compound 1 for 72 
h. After treatment, cells were washed, collected and were centrifuged. Pellets were suspended 
in PBS and cells were counted. To demonstrate viability of the cells, cisplatin staining was 
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carried out on ice for 3 min. Samples were diluted with Maxpar Cell Staining Buffer (MCSB), 
centrifuged and were incubated with TruStain FcX, to prevent non-specific binding of the 
antibodies. Samples were centrifuged, suspended and the resultant antibody mix was added to 
fresh master pool of antibodies. After 60 min of incubation at 4°C, the cells were washed and 
centrifuged, and the pellets were re-suspended in the residual volume. Fixation of the samples 
was accomplished in 1.6% formaldehyde. Next, the cells were centrifuged, and the Cell-ID 
DNA intercalator was added to the samples for overnight incubation. After additional washing 
steps, the samples were centrifuged and the pellets were suspended in 1 mL PBS. For the 
measurement, the cell number was set in a cell acquisition solution, containing 10% EQ 
Calibration Beads and the samples were percolated with gravity filter. After manual gating 
singlets were analysed by the Cytobank platform. 
3.14 In vivo mouse model of breast cancer 
BALB/c mice were housed in sterile, IVC cage system, equipped with a HEPA filter at 
ambient temperature of 25°C. At the first day of the experiment, 4T1 breast carcinoma cells 
suspended in FBS-free RPMI medium, were injected into the mammary pad of the mice. On 
the 12th day of the experiment, animals were randomized into two groups. Members of the test 
group were treated intraperitoneally with 25 mg/kg dose of compound 1, dissolved in mixture 
of DMSO : Solutol HS 15 : saline (1:3:10) once per day, five times per week for 2 weeks. 
Animals of the control group were treated with the vehicle mixture. Tumor size and body mass 
were determined daily, and on the 15th day of treatment period, animals were terminated. 
Finally, weight of the surgically removed tumor tissues were measured. 
3.15 Statistical analysis 
For statistical analyses, GraphPad Prism version 5.01 software was used. The statistical 
significance was estimated by one-way analysis of variance (ANOVA), followed by the 
Dunnett post-test. In the Results section, all data are presented as means ± SEM of at least three 






4.1 MTT assay 
Compound 1 exerted considerable antiproliferative activity against breast and cervical 
cancer cell lines, while compound 2, 3 and 4 showed no substantial effect on cell proliferation; 
thus, compound 1 was selected for further experimentation. For comparison, the IC50 values of 
therapeutically applied cisplatin used as reference agent, are presented for the same cell lines. 
Cell line Calculated IC50 value (μM) 
Compound 1 2 3 4 CIS 
HeLa 1.13 >30 >30 >30 13.75 
SiHa 0.78 >30 >30 >30 13.51 
C33A 1.72 >30 >30 >30 3.09 
A2780 2.34 >30 >30 29.58 1.30# 
MCF-7 1.40* >30 >30 >30 5.78# 
T47D 1.20* >30 >30 >30 9.78# 
MDA-MB-361 1.60* >30 >30 >30 3.74# 
MDA-MB-231 1.80* >30 >30 >30 19.13# 
Table 1. Calculated IC50 values of compound 1-4 and cisplatin (CIS) determined on eight human breast- 
or gynaecological cancer cell lines. * and # are data from literature 
In order to obtain information about tumor-selectivity, quotients of IC50 values 
determined on cancerous and non-cancerous (NIH/3T3) cells were prepared. In case of 
compound 1, these tumor selectivity indices were <1 but >0.1, which indicate moderate 
selectivity. 
4.2 Hoechst/Propidium iodide fluorescent double staining 
Changes in cell morphology and the membrane integrity of MCF-7 and SiHa cells were 
observed 24 h post-treatment. Fluorescent images revealed decreased number of viable cells, 
and significant elevation in the number of nuclei emitting light blue fluorescence due to DNA 
condensation in early apoptosis and red fluorescence in secondary necrotic cells with damaged 
cell membrane in a concentration-dependent manner. 
4.3 Apoptosis assay 
In all cancer cell lines, compound 1 triggered a concentration-dependent elevation of 
phosphatidylserine exposure as an indicator of apoptotic process (early apoptosis: AnnV+/PI–; 





Figure 2. Compound 1 induced accumulation of early and/or late apoptotic cell populations. Changes 
in intact (AnnV–/PI–), early apoptotic (AnnV+/PI–), late apoptotic (AnnV+/PI+), and necrotic (AnnV–
/PI+) populations of MCF-7 (A), MDA-MB-231 (B), SiHa (C) and C33A (D) cells are presented in 
percentage. *, ** and *** indicate p<0.05, p<0.01 and p<0.001, respectively. 
4.4 Cell cycle analysis 
 
Figure 3. Test compound 1 induced cell cycle disturbances via accumulation of cells in the G2/M phase 
and reduction of the G0/G1 phase. Experiments were carried out on MCF-7 (A), SiHa (C) and C33A 
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(D) cell lines 48 h post-treatment, while in the case of triple negative breast cancer cell line (B), 72 h 
incubation time showed favourable effect. *, ** and *** indicate p<0.05, p<0.01 and p<0.001 
respectively, compared to the untreated control. 
Concentration-dependent elevation of hypodiploid sub-G1 population, regarded as 
marker of apoptotic process, were recorded at ≥2 µM in all of the four examined cell lines 
(MCF-7, MDA-MB-231, SiHa, C33A) after 48 h treatment. Besides these findings, significant 
accumulation of cells in G2/M phase to the detriment of G0/G1 phase were observed in all 
examined malignant cell lines. 
4.5 Determination of caspase-3 activity 
The androstadiene analogue (1) enhanced the caspase-3 activity by 1.6 to 2.6-fold after 
24, 48 and 72 h exposure at ≥2 μM concentrations on the SiHa cell line. 
4.6 Mitochondrial membrane potential assay (JC-1 staining) 
In MCF-7, MDA-MB-231, SiHa and C33A samples stained by JC-1 dye, a 
concentration-dependent elevation in the percentage of subpopulations emitting green 
fluorescence were detected. 
 
Figure 4. Considerable, concentration-dependent alterations in mitochondrial membrane integrity were 
observed in MCF-7 (A) and MDA-MB-231 cells (B) 12 h post-treatment and in SiHa (C) and C33A (D) 
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cells after 24 h incubation with the test substance (1). *, ** and *** represent p<0.05, p<0.01 and 
p<0.001 respectively, compared to the control. 
4.7 Yeast androgen screen assay (YAS) 
In the presence of an androgen-sensitive, genetically modified yeast strain (S. 
cerevisiae), no substantial androgenic or antiandrogenic activity of compound 1 were identified 
compared to DHT in the agonistic and to flutamide in antagonistic determination, used as 
reference agents after 48 h exposure. 
4.8 Wound-healing assay 
Image analysis confirmed noteworthy decrease in migratory capacity of MCF-7 cells by 
30.8% and 22.8% at 0.3 µM compared to control after 24 or 48 h treatment. Similarly, influence 
of compound 1 to migration of SiHa cells manifested in a significant reduction of wound-
closure by 9.0% and 21.7% at 0.03 µM 24 h or 48 h post-treatment, respectively. 
4.9 Boyden chamber assay 
In this system, the number of invading MDA-MB-231 triple negative breast cancer cells 
were decreased by approximately 70% at 0.3 µM. Furthermore, number of invading cervical 
SiHa cells were significantly diminished by 48.9% after application of 0.03 µM of compound 
1 for 24 h. 
 
Figure 5. Anti-invasive properties of the test substance (1) were demonstrated by considerable decrease 
in percentage of invading MDA-MB-231 (A) and SiHa (B) cells in the treated samples compared to 




4.10 CCIDs assay 
Cancer spheroids – consisting of MCF-7 cells – induced gap-formation in the monolayer 
of iLEC cells; this process was significantly inhibited by treatment with compound 1 or 
defactinib, which served as positive control. However, the structurally-similar epiandrosterone, 
only exerted a minor anti-invasive effect at 40 µM. 
 
Figure 6. Our test substance (A) and defactinib (B) decreased size of cell-free areas at 2 µM 4 h post-
treatment. *** indicates p<0.001 compared to the control. 
4.11 Single Cell Mass Cytometry 
To characterize the tumor marker profile of chemosensitive subpopulations of the 
MDA-MB-231 cell line, nine carcinoma markers were investigated at single cell resolution. 
Substantial decrease was detected in the percentage of cells positive for EGFR, CD274 (PD-
L1), and CD326 (EpCAM) within the drug-sensitive population upon the treatment of 
compound 1. On the other hand, elevated expression levels of GLUT1, MCT4, Pan-Keratin, 
CD66 (a,c,e), Gal-3 and TMEM45A were observed in the chemosensitive populations. 
4.12 In vivo mouse breast cancer model 
After 2 weeks of intraperitoneal administration of 25 mg/kg dose, a significant reduction 
in weight of the induced tumor tissues was observed. In addition, noteworthy deceleration in 
tumor growth rate was revealed in the treated group from the fourth day of the application 





Figure 7. After 14 days of intraperitoneal application, the mean weight of surgically removed tumor 
tissues (n=7) was considerable decreased in the experimental group (A). Tumor growth curves (B) 
demonstrate a significant tumor growth inhibitory effect of compound 1 in vivo. *, ** and *** indicate 





In the human body, sexual steroids exhibit great impact on cell proliferation, but 
precisely because of this, they may also be responsible for the development and progression of 
several hormone-dependent malignancies, such as breast or prostate cancer. On the other hand, 
modification of their structure at relevant positions, especially on the A- and/or D-ring, may 
yield novel anticancer agents. The aim of the present study was to evaluate the pharmacological 
potential of four D-ring modified androstane derivatives, with special regard to their 
antiproliferative and antimetastatic properties on breast and gynaecological cancer cells. 
The antiproliferative effect of compound 2, 3 and 4 did not reach the threshold of at 
least 50% of inhibition at 30 µM concentration in most of the cases. IC50 values of the candidate 
compound (1) were lower than 2 µM on cervical and breast cancer cell lines, which exhibits at 
least a two-fold increase in sensitivity, compared to the impact of therapeutically-applied 
cisplatin used as a reference agent. Furthermore, tumor selectivity indices of compound 1 
calculated as described above, were ranged from 0.2 to 0.7; in contrast, indices of cisplatin 
presented with an absolute lack of selectivity, which manifested in higher values than 1.1 on 
cervical and breast cancer cells. Chromatin condensation in early apoptotic cells and loss of 
membrane integrity in necrotic and secondary necrotic cells were visualised under a fluorescent 
microscope by Hoechst33258/PI staining after 24 h incubation with the test substance, which 
indicated a significant increase in apoptotic and necrotic cell population as well in MCF-7 and 
SiHa samples. To resolve limitations of this microscopic method, and for an even more detailed 
separation of different cell fractions such as early vs. late apoptotic and necrotic cells, Annexin 
V-Alexa488/PI fluorescent double staining was performed by flow cytometry. Significantly 
elevated subpopulations of late apoptotic (AnnV+/PI+) cells were detectable at ≥2 µM without 
greater accumulation of necrotic (AnnV–/PI+) cells on all of the utilized cell lines. In addition, 
a proapoptotic characteristic was confirmed by the elevated proportion of sub-G1 subpopulation 
in the cell cycle analysis on the utilized four malignant cell lines (MCF-7, MDA-MB-231, 
C33A, SiHa) as well. In all cases, a considerable arrest and accumulation of cells in the G2/M 
phase were observed in the expense of cells in the G0/G1 phase. A major enzyme of the 
execution phase, responsible for chromatin condensation and DNA fragmentation, is caspase-
3; the activity of this enzyme was elevated to more than 1.5-fold after 24, 48 or 72 h exposure 
to 2 µM of compound 1. Although, the caspase-3 enzyme may be activated during both the 
intrinsic and the extrinsic pathway of apoptosis, JC-1 staining indicated a disruption of 
mitochondrial membrane potential and integrity after 12 hours of exposure on breast carcinoma 
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cell lines and after 24 h of treatment on cervical cell lines, corroborating the intrinsic origin of 
apoptosis. Based on previous results and structure-activity relationships, we hypothesized that 
a bulky steric structure such as the 1'-4''-cyanophenyl-4'-hydroxymethyl-1'H-pyrazol-3'-yl 
moiety at position C-17 of the androstadiene skeleton, may diminish or prevent binding of the 
test compound to the androgen receptor. Lack of androgen or antiandrogen activity have been 
confirmed by YAS assay on a genetically modified S. cerevisiae strain.  
In the first stage of metastasis progression, the migration of cancer cells to neighbouring 
tissues and the invasion through the basement membrane occurs. In the in vitro experimental 
systems, the drug candidate (1) significantly inhibited migration of SiHa and MCF-7 cells and 
invasion of highly invasive MDA-MB-231 and SiHa cells at nanomolar concentrations even 
after 24 h of treatment. In a 3D, co-culture CCIDs assay, compound 1 reduced the size of cell 
free-areas on a lymphatic endothelial monolayer underneath the MCF-7 tumor emboli by 30% 
after 4 h of treatment at 8 µM and showed comparable inhibition to defactinib, a potent FAK-
inhibitor at lower concentrations. These values are more pronounced than inhibition by 
epiandrosterone, a structural analogue, in the same system. 
Treatment with compound 1 decreased the expression of EGFR, CD274, and CD326 in 
the sensitive subpopulations of MDA-MB-231 cells, while increased level of GLUT1, MCT4 
Pan-Keratins, CD66, Gal-3, and TMEM45A were observed. These data probably indicate the 
increased chemosensitivity and the metabolic reprogramming of cells as a compensatory 
mechanism, activated upon the test substance-induced oxidative stress. Interestingly, the 
population of CD66(a,c,e)-positive cells showed overlapping with the TMEM45A-positive 
cells. 
Finally, antitumor properties of the examined androstadiene derivative (1) were tested 
on the 4T1 breast cancer model. After 2 weeks of intraperitoneal administration, size of 
developing tumors were approximately 50% relative to control samples without severe, life-
threatening side effects. 
In conclusion, our experimental data revealed favourable antiproliferative and 
antimetastatic characteristics of compound 1. Proapoptotic properties via activation of the 
intrinsic pathway with moderate tumor selectivity and potent antimigratory, anti-invasive and 
anti-intravasative effects, without hormonal potential have been identified as part of the 
mechanism of action. In the light of these results, substitution of the androsta-5,16-diene 
framework at C-17 position with heterocyclic moieties should be considered for the design and 
synthesis of novel, effective antitumor agents. 
